Evidation Health, a San Mateo, CA-based startup that helps healthcare companies quantify outcomes in the digital era, with real life data from connected patients has raised $10 million in funding led by Sanofi-Genzyme BioVentures. The startup plans to utilize the latest round of funding to enhance its capabilities in large scale behavioral analytics, health outcomes measurement, and digital biomarker development using real life patient data from hundreds of applications and devices.
Founded in 2015 by GE Ventures and Stanford Health Care, Evidation Health enables healthcare companies to rapidly leverage novel, digitally captured data sets that represent the real-life of the patient and their health outcomes. The company developed its Real Life Study Platform to accelerate and enhance outcomes research through virtualized pragmatic trials at scale—quantifying the impact of digital and traditional interventions far more efficiently than conventional approaches. Evidation Health works across the healthcare ecosystem with top pharmaceutical companies, payers, providers, and digital health companies.
“At Evidation Health, we focus on measuring behavior-driven outcomes to help our partners understand and maximize product impact in the real world,” says Deborah Kilpatrick, CEO of Evidation Health in a statement. “We are excited about the Sanofi investment, as it aligns with our creation of faster, better ways to quantify patient outcomes—which we believe will directly fuel innovation across healthcare and life sciences.”
